Analyst consensus rating
Edgewise Therapeutics Analyst Rating: Buy
Direct answer
Edgewise Therapeutics's consensus rating is Buy.
13 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $51.69.
Forecast evidence checked September 6, 2026.
Get free Edgewise Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $43.07
- Average price target
- $51.69
- High price target
- $66.00
- Low price target
- $36.00
- Low target gap
- -16.4%
- Target upside
- +20%
- High target gap
- +53.2%
- Target range width
- 69.7%
- Consensus rating
- Buy
- Analysts
- 13
- Evidence date
- September 6, 2026
- Valid through
- September 13, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Edgewise Therapeutics?
Edgewise Therapeutics has a verified Buy consensus. The same dataset has an average price target of $51.69.
How far are Edgewise Therapeutics's low and high targets from the recorded price?
The low target implies -16.4%, while the high target implies +53.2%.
How many analysts are included in Edgewise Therapeutics's consensus?
The verified consensus includes 13 analysts.
How is Edgewise Therapeutics's target upside or downside calculated?
The average target of $51.69 is divided by the recorded price of $43.07, then one is subtracted to produce +20%. This does not guarantee a future return.
When was Edgewise Therapeutics's analyst forecast verified?
The data was verified on 2026-09-06. The dataset is valid through 2026-09-13.